It was globally approved on September 21, 2018, in Japan for OAB.Vibegron has been proven effective in 5 key clinical trials.A phase IIb global trial completed in 2013 of 1395 patients, of which 89.7% were women and 63.3% had not been treated previously, demonstrated a significant decrease in daily micturitions and urgent urinary incontinence episodes upon administration of vibegron.An international phase III trial of 506 participants completed in 2019 found statistically significant efficacy of vibegron after 2 weeks of daily administration. The adverse effect rates in patients treated with vibegron were comparable to those in patients who received a placebo.GEMTESA, a drug using vibegron as an active ingredient was approved by the FDA on December 23, 2020, after an additional phase III international trial of 1085 patients. Society and culture
Legal status
Vibegron was approved for medical use in the United States in December 2020. Names
Vibegron is the international nonproprietary name (INN). Mechanism of action
Vibegron is a selective agonist for the beta-3 adrenergic receptor (β3-AR). The receptors are located in the kidneys, urinary tract and bladder tissue. Upon binding, the β3 receptor undergoes a conformational change. This induces the activation of adenylate cyclases via G proteins and thereby promotes the formation of cyclic adenosine monophosphate (cAMP). The consequence of this cascade is an increased intracellular cAMP concentration which triggers activation of cAMP-dependent protein kinase A and causes a reduction of Ca2+ concentration in the cytoplasm. The kinase then phosphorylates myosin chains and thereby inhibits muscle contraction.The final effect of vibegron is muscle relaxation in the bladder.
The term acne cosmetica refers to acne caused by or aggravated by cosmetics. : 240   The mechanism is thought to be chemically induced plugging of the pilosebaceous orifice. This became a significant problem for dermatologists in the 1970s and 1980s, but with the improved formulations produced by cosmetic chemists in the decades since, a diagnosis of acne cosmetica has become relatively rare in dermatological practice. The terms "non-comedogenic" and "non-acne(i)genic" appeared on moisturizers and other cosmetic compounds as manufacturers introduced re-formulations—sometimes associated with claims that the products were "oil-free" or "water-based". Although early work produced lists of comedogenic chemicals in various strengths and vehicles, it became apparent that one could not predict the actual comedogenicity of a product from its contents; rather, the finished product itself needed use-testing.The production of a low-grade folliculitis by some components of cosmetic products has led to misdiagnosis on occasion. People may not attribute skin reactions to their cosmetics at first, but may notice worsening symptoms after using certain face makeup, sunblock or lip products. Reactions are more likely to occur if applied cosmetics are left on and not stripped after wearing them. See also
List of cutaneous conditions

References


== External links ==